Introduction

Coronary heart disease is the single leading cause of death in Australia. Cardiovascular disease (CVD) is responsible for almost a third of all deaths.1,2 Statins remain the cornerstone of CVD prevention through their lipid lowering effects and significant impact on major cardiovascular events and mortality.3

Learning objectives

After successful completion of this CPD activity, pharmacists should be able to:

  • Describe the use of statin medicines for at-risk populations
  • Discuss muscle related statin intolerance and how it is managed
  • Identify the evidence for coenzyme Q10, vitamin K2 and selenium supplementation in the context of cardiovascular disease

Competency standards addressed (2016): 1.1, 1.5, 2.2, 3.5

Accreditation number: CAP1911CAMNR

Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.  

Statin intolerance, particularly muscle related adverse effects (statin related muscular symptoms or SAMS), are the leading cause of statin discontinuation.4 Identifying true SAMS involves taking a detailed patient history; assessing the nature and timing of the muscle symptoms, and measuring any associated elevations in creatine kinase.5 Up to two in three Australians use comp

THIS IS A CPD ARTICLE. YOU NEED TO BE A PSA MEMBER AND LOGGED IN TO READ MORE.